Neuren Pharmaceuticals Ltd (NEU) — Cash Flow Quality Index
Neuren Pharmaceuticals Ltd (NEU) has a Cash Flow Quality Index of 8.54x as of June 2025. Operating cash flow of AU$128.31 Million exceeds net income of AU$15.03 Million, indicating high earnings quality where cash backs reported profits. Explore Neuren Pharmaceuticals Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Neuren Pharmaceuticals Ltd Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Neuren Pharmaceuticals Ltd across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Neuren Pharmaceuticals Ltd (NEU) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Neuren Pharmaceuticals Ltd (2009–2024)
Year-by-year earnings quality comparison for Neuren Pharmaceuticals Ltd. For live market cap and the full company financial profile, see Neuren Pharmaceuticals Ltd market capitalisation.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.08x | AU$-11.27 Million | AU$142.04 Million | ▼ -106.7% |
| 2023 | 1.18x | AU$184.93 Million | AU$157.08 Million | ▼ -94.0% |
| 2022 | 19.56x | AU$3.60 Million | AU$184.00K | ▲ +838.0% |
| 2018 | 2.09x | AU$6.41 Million | AU$3.07 Million | ▲ +222.7% |
| 2017 | -1.70x | AU$-5.59 Million | AU$3.29 Million | ▲ +86.8% |
| 2009 | -12.93x | AU$-1.29 Million | AU$99.56K | — |